File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12072-019-09928-5
- Scopus: eid_2-s2.0-85060606790
- PMID: 30671807
- WOS: WOS:000461301000006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection
Title | Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection |
---|---|
Authors | |
Keywords | Cirrhosis Elastography Hepatitis B Liver fibrosis M2BPGi |
Issue Date | 2019 |
Publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 |
Citation | Hepatology International, 2019, v. 13 n. 2, p. 148-156 How to Cite? |
Abstract | Background and aim:
Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM).
Methods:
CHB patients with LSM by transient elastography technology and retrievable serum samples were recruited. Ten-year re-assessments of LSM and M2BPGi were repeated in a patient subgroup.
Results:
240 CHB patients (M:F = 116:124; median age 47.5 years) were recruited. The median M2BPGi values for F0/F1/F2, F3 and F4 progressively increased with more advanced stages of liver fibrosis: 0.39, 0.46 and 0.82 COI, respectively (p < 0.01). M2BPGi levels correlated well with liver stiffness (r = 0.611), FIB-4 (r = 0.616), and strongly with APRI (r = 0.825) (all p < 0.001). Using cut-off values of 0.605 and 0.615 COI, the AUROCs were 0.754 and 0.799 for ≥ F3 and F4, respectively. M2BPGi identified one-quarter patients at risk of advanced fibrosis/cirrhosis otherwise classified into ‘grey area’ by LSM. In 86 patients with reassessment LSM, 21 (24.4%) showed significant fibrosis regression with corresponding decline in median M2BPGi level (− 0.11 COI) compared with the increase of +0.03 COI in patients without significant fibrosis regression (p = 0.011). Male gender, older age, use of potent antiviral therapy and change in serum M2BPGi were independently associated with significant fibrosis regression.
Conclusions:
Serum M2BPGi can risk-stratify CHB patients whose liver stiffness fell into the ‘grey area’. Significant fibrosis regression occurring in one-quarter patients was reflected by a reduction in M2BPGi levels at 10-year interval. |
Persistent Identifier | http://hdl.handle.net/10722/267418 |
ISSN | 2023 Impact Factor: 5.9 2023 SCImago Journal Rankings: 1.813 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Ning, Q | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2019-02-18T09:01:36Z | - |
dc.date.available | 2019-02-18T09:01:36Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Hepatology International, 2019, v. 13 n. 2, p. 148-156 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | http://hdl.handle.net/10722/267418 | - |
dc.description.abstract | Background and aim: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM). Methods: CHB patients with LSM by transient elastography technology and retrievable serum samples were recruited. Ten-year re-assessments of LSM and M2BPGi were repeated in a patient subgroup. Results: 240 CHB patients (M:F = 116:124; median age 47.5 years) were recruited. The median M2BPGi values for F0/F1/F2, F3 and F4 progressively increased with more advanced stages of liver fibrosis: 0.39, 0.46 and 0.82 COI, respectively (p < 0.01). M2BPGi levels correlated well with liver stiffness (r = 0.611), FIB-4 (r = 0.616), and strongly with APRI (r = 0.825) (all p < 0.001). Using cut-off values of 0.605 and 0.615 COI, the AUROCs were 0.754 and 0.799 for ≥ F3 and F4, respectively. M2BPGi identified one-quarter patients at risk of advanced fibrosis/cirrhosis otherwise classified into ‘grey area’ by LSM. In 86 patients with reassessment LSM, 21 (24.4%) showed significant fibrosis regression with corresponding decline in median M2BPGi level (− 0.11 COI) compared with the increase of +0.03 COI in patients without significant fibrosis regression (p = 0.011). Male gender, older age, use of potent antiviral therapy and change in serum M2BPGi were independently associated with significant fibrosis regression. Conclusions: Serum M2BPGi can risk-stratify CHB patients whose liver stiffness fell into the ‘grey area’. Significant fibrosis regression occurring in one-quarter patients was reflected by a reduction in M2BPGi levels at 10-year interval. | - |
dc.language | eng | - |
dc.publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 | - |
dc.relation.ispartof | Hepatology International | - |
dc.subject | Cirrhosis | - |
dc.subject | Elastography | - |
dc.subject | Hepatitis B | - |
dc.subject | Liver fibrosis | - |
dc.subject | M2BPGi | - |
dc.title | Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection | - |
dc.type | Article | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s12072-019-09928-5 | - |
dc.identifier.pmid | 30671807 | - |
dc.identifier.scopus | eid_2-s2.0-85060606790 | - |
dc.identifier.hkuros | 296827 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 148 | - |
dc.identifier.epage | 156 | - |
dc.identifier.isi | WOS:000461301000006 | - |
dc.publisher.place | India | - |
dc.identifier.issnl | 1936-0533 | - |